Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518974 | 0.86 | SYK (0.57) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL5609143 | 0.85 | APP (0.55) | APPHTTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL11410721 | 0.85 | TP53 (0.52) | APPTP53CYP3A4HTTHSD17B10 | |
| SCHEMBL13169873 | 0.83 | THRB (0.60) | APPKMT2ANR1H4CYP1A2CYP2C19 | |
| SCHEMBL146848 | 0.82 | TP53 (0.53) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL4050094 | 0.82 | TP53 (0.63) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL27926957 | 0.82 | TP53 (0.53) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL27934212 | 0.82 | HTT (0.55) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4048844 | 0.81 | TP53 (0.61) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL7986906 | 0.81 | MAPT (0.54) | TP53CYP3A4HTTHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524600-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS | SANOFI SA (FR) | 2021-11-17 | — | — | EP | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2380879-B1 | Tetrahydroindolone and tetrahydroindazolone derivatives | ESANEX INC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170107230-A1 | P38 AND JNK MAPK INHIBITORS FOR THE TREATMENT AND PROPHYLAXIS OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | ALLINKY BIOPHARMA (ES) | 2017-04-20 | — | — | US | disclosed |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2014-11-20 | — | — | US | disclosed |
| CN-101939326-B | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN UNIVERSITY | 2013-06-05 | — | — | CN | disclosed |
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| US-4172944-A | Water insoluble styryl dyestuffs having hetero-aryl methylene substituent | BAYER AKTIENGESELLSCHAFT (DE) | 1979-10-30 | — | — | US | disclosed |
| US-4046771-A | GREENISH-YELLOW SHADES ON SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-06 | — | — | US | disclosed |
| US-4016191-A | WATER INSOLUBLE; LIGHTFASTNESS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107230-A1 | P38 AND JNK MAPK INHIBITORS FOR THE TREATMENT AND PROPHYLAXIS OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | MAPK1, MAPK14, MAPK11 | APP 392/4885TP53 2797/4885CYP3A4 3349/4885 |
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | APP 2582/4885TP53 96/4885CYP3A4 45/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | APP 3905/4885TP53 3390/4885CYP3A4 128/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | APP 2582/4885TP53 96/4885CYP3A4 45/4885 |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | APP 2582/4885TP53 96/4885CYP3A4 45/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | APP 3282/4885TP53 4055/4885CYP3A4 49/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | APP 3282/4885TP53 4055/4885CYP3A4 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.